Erasca Inc (ERAS)vsRevolution Medicines Inc (RVMD)
ERAS
Erasca Inc
$17.72
-2.42%
HEALTHCARE · Cap: $6.63B
RVMD
Revolution Medicines Inc
$180.92
-1.60%
HEALTHCARE · Cap: $39.58B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. ERAS earns a higher WallStSmart Score of 25/100 (F).
ERAS
Avoid25
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
Trading at 14.0x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ERAS
The strongest argument for ERAS centers on Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : ERAS
The primary concerns for ERAS are Price/Book, Revenue Growth, EPS Growth.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.38 — expect wider price swings.
ERAS is growing revenue faster at 0.0% — sustainability is the question.
ERAS generates stronger free cash flow (-27M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ERAS scores higher overall (25/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Erasca Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers, aiming to meet significant unmet needs in oncology. Utilizing its proprietary drug discovery platform that merges advanced genomics with precision medicine, the company is committed to creating treatments that directly target the mutations responsible for cancer progression. Erasca boasts a strong pipeline of clinical-stage candidates designed to inhibit crucial tumor growth pathways, reinforcing its position as a leader in improving therapeutic standards and patient outcomes in cancer care. Strategic partnerships within the oncology research community bolster Erasca's reputation as a vital innovator in the biopharmaceutical landscape.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?